Axsome Therapeutics Inc [AXSM] stock is trading at $110.11, up 2.28%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AXSM shares have gain 5.90% over the last week, with a monthly amount drifted -1.87%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Axsome Therapeutics Inc [NASDAQ: AXSM] stock has seen the most recent analyst activity on June 03, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $185. Previously, Jefferies started tracking the stock with Buy rating on April 07, 2025, and set its price target to $200. On February 11, 2025, Deutsche Bank initiated with a Buy rating and assigned a price target of $176 on the stock. Mizuho reiterated its Outperform rating and decreased its price target to $122 on December 31, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $140 as its price target on September 03, 2024. BofA Securities upgraded its rating to Buy for this stock on August 06, 2024, and upped its price target to $106. In a note dated July 22, 2024, Needham initiated an Buy rating and provided a target price of $130 on this stock.
Axsome Therapeutics Inc [AXSM] stock has fluctuated between $64.11 and $139.13 over the past year. Currently, Wall Street analysts expect the stock to reach $189.33 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $110.11 at the most recent close of the market. An investor can expect a potential return of 71.95% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
Axsome Therapeutics Inc [NASDAQ:AXSM] reported sales of 432.16M for the trailing twelve months, which represents a growth of 61.95%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.63%, Pretax Profit Margin comes in at -0.64%, and Net Profit Margin reading is -0.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -3.64 and Total Capital is -0.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 108.46 points at the first support level, and at 106.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 111.58, and for the 2nd resistance point, it is at 113.06.
Ratios To Look Out For
For context, Axsome Therapeutics Inc’s Current Ratio is 2.03. As well, the Quick Ratio is 1.96, while the Cash Ratio is 1.23. Considering the valuation of this stock, the price to sales ratio is 12.54, the price to book ratio is 101.86.
Transactions by insiders
Recent insider trading involved Coleman Mark, Director, that happened on May 27 ’25 when 3750.0 shares were sold. Director, Coleman Mark completed a deal on May 28 ’25 to sell 3750.0 shares. Meanwhile, Chief Operating Officer Jacobson Mark L. sold 20673.0 shares on May 27 ’25.
